Replies to post #7 on Candel Therapeutics Inc (CADL)

[subslover]

Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
November 07 2022 - 08:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced new clinical data will be presented in the upcoming 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, MA and the 27th Annual Meeting of the Society for Neuro-Oncology (SNO) in Tampa Bay, FL.
Details are as follows:

37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Poster Presentation Title: Dynamic analyses of tumor microenvironment modulation by CAN-2409 treatment using Kaede photoconvertible transgenic mice

Presenter: Anne R. Diers, PhD, Director of Early Research, Candel Therapeutics
Abstract Number: 1134
Date/Time: Friday, November 11, 2022, from 9 am – 8:30 pm ET
Location: Hall C, Omni Boston Hotel, Boston, MA or Virtual

Oral Presentation Title: First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma

Presenter: Patrick Y. Wen, MD, Director, Cancer for Neuro-Oncology, Dana-Farber Cancer Institute; Professor, Neurology, Harvard Medical School; Principal Investigator for Candel Therapeutics
Abstract Session: Late Breaking 204
Date/Time: Friday, November 11, 2022, from 11:25 am – 11:55 am ET
Location: Hall B2, Omni Boston Hotel, Boston, MA or Virtual

27th Annual Meeting of the Society for Neuro-Oncology (SNO)

Oral Presentation Title: Enriched TCR/BCR VDJ rearrangements correlate with MRI and survival outcomes in patients with recurrent high-grade glioma treated with CAN-3110

Presenter: Alexander Ling, PhD, Postdoctoral Research Fellow, Brigham and Women’s Hospital
Abstract Session: Clinical Trial I
Date/Time: Friday, November 18, 2022, from 5:30 pm – 5:35 pm ET
Location: Ballroom B, Tampa Convention Center, Tampa, FL
Details from the presentations will be available following the events on the Candel website at https://www.candeltx.com/media/.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on helping patients fight cancer with viral immunotherapies that elicit a systemic anti-tumor immune response. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and CAN-3110 is the lead product candidate from the HSV platform. The enLIGHTEN™ Discovery Platform is the first systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, include key data readout milestones; expectations regarding the therapeutic benefit of its programs; and expectations regarding cash runway and expenditures. The words “may,” “wil